CN112218655A - 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产 - Google Patents

以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产 Download PDF

Info

Publication number
CN112218655A
CN112218655A CN201980030194.0A CN201980030194A CN112218655A CN 112218655 A CN112218655 A CN 112218655A CN 201980030194 A CN201980030194 A CN 201980030194A CN 112218655 A CN112218655 A CN 112218655A
Authority
CN
China
Prior art keywords
epitope
peptide
epitopes
antigen presenting
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980030194.0A
Other languages
English (en)
Chinese (zh)
Inventor
王长怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ubi Ip
Ubi Ip Holding Co
Original Assignee
Ubi Ip Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holding Co filed Critical Ubi Ip Holding Co
Publication of CN112218655A publication Critical patent/CN112218655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980030194.0A 2018-05-04 2019-05-03 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产 Pending CN112218655A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667123P 2018-05-04 2018-05-04
US62/667,123 2018-05-04
PCT/US2019/030649 WO2019213555A1 (en) 2018-05-04 2019-05-03 Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response

Publications (1)

Publication Number Publication Date
CN112218655A true CN112218655A (zh) 2021-01-12

Family

ID=68386088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980030194.0A Pending CN112218655A (zh) 2018-05-04 2019-05-03 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产

Country Status (12)

Country Link
US (2) US20220023400A1 (https=)
EP (1) EP3790581A4 (https=)
JP (2) JP2021523127A (https=)
KR (1) KR20210010873A (https=)
CN (1) CN112218655A (https=)
AU (1) AU2019262609A1 (https=)
BR (1) BR112020022443A2 (https=)
CA (1) CA3099296A1 (https=)
MX (1) MX2020011733A (https=)
SG (1) SG11202010942WA (https=)
TW (1) TWI754817B (https=)
WO (1) WO2019213555A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876570A (zh) * 2021-02-09 2021-06-01 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020240332A1 (ja) * 2019-05-31 2020-12-03 株式会社半導体エネルギー研究所 半導体装置の作製方法
KR20250040007A (ko) * 2022-07-14 2025-03-21 백시니티, 인크. Tau 펩타이드 면역원 작제물
CN118812726B (zh) * 2024-06-26 2025-05-16 西北民族大学 脑心肌炎多抗原表位重组蛋白及其在制备脑心肌炎疫苗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143087A1 (en) * 2013-03-15 2014-09-18 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US20140088020A1 (en) * 1999-08-30 2014-03-27 David S Terman Composition and Methods for Treatment of Cancer
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ATE506072T1 (de) * 2002-09-12 2011-05-15 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
JP5863582B2 (ja) * 2012-07-02 2016-02-16 東京エレクトロン株式会社 プラズマ処理装置、及び温度制御方法
JP6502267B2 (ja) * 2013-02-18 2019-04-17 スプリング バンク ファーマシューティカルズ，インコーポレイテッド ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計
US10450352B2 (en) * 2016-03-23 2019-10-22 Board Of Regents, The University Of Texas System Engineered polypeptides for antigen delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143087A1 (en) * 2013-03-15 2014-09-18 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHANG YI WANG ET AL: "UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer\'s disease", 《ALZHEIMER’S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS》, vol. 3, no. 2, pages 262 - 272 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876570A (zh) * 2021-02-09 2021-06-01 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法
CN112876570B (zh) * 2021-02-09 2022-07-26 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法

Also Published As

Publication number Publication date
AU2019262609A1 (en) 2020-12-03
WO2019213555A1 (en) 2019-11-07
SG11202010942WA (en) 2020-12-30
US20220023400A1 (en) 2022-01-27
BR112020022443A2 (pt) 2021-02-09
CA3099296A1 (en) 2019-11-07
JP2021523127A (ja) 2021-09-02
TWI754817B (zh) 2022-02-11
US20250262286A1 (en) 2025-08-21
EP3790581A4 (en) 2022-06-22
MX2020011733A (es) 2021-01-15
KR20210010873A (ko) 2021-01-28
EP3790581A1 (en) 2021-03-17
JP2024095743A (ja) 2024-07-10
TW201946649A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
JP7555598B2 (ja) 合成ペプチド免疫原のための免疫刺激薬としての人工無差別ｔヘルパー細胞エピトープ
US20250262286A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
AU764961B2 (en) Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
Schirmbeck et al. Similar as well as distinct MHC class I‐binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen
CN113574073B (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
TWI507413B (zh) 脂質化多抗原表位疫苗
AU2006301171B2 (en) Immunostimulatory combination for the prophylactics and treatment of hepatitis C
JP5901084B2 (ja) ペプチドアジュバント
HK40045220A (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
EP4554618A2 (en) Tau peptide immunogen constructs
Mažeikė Generation of anticancer vaccine based on virus-like particles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045220

Country of ref document: HK